Table 1.
Summary—miRNAs influencing the prostaglandin pathway by binding to mRNAs of key enzymes or interfering with RNA-binding protein CUGBP1 (see mPGES-1).
| miRNA | Target | Tissue/disease | Reference |
|---|---|---|---|
| Hsa-miR-144 | COX-2 | Premature labor | (Li et al., 2016) |
| Hsa-miR-144-5p | COX-2 | Periodontitis | (Li et al., 2019) |
| Hsa-miR-144 | COX-2 | Esophageal squamous cell cancer | (Shao et al., 2016) |
| Hsa-miR-26a | |||
| Hsa-miR-26b | COX-2 | Nasopharyngeal epithelial cancer | (Ji et al., 2010) |
| Hsa-miR-26b | COX-2 | Oral lichen planus | (Danielsson et al., 2012) |
| Hsa-miR-26b | COX-2 | Breast cancer | (Li et al., 2013) |
| Hsa-miR-216a-3p | COX-2 | Colorectal cancer | (Wang et al., 2018) |
| Hsa-miR-30a | COX-2 | Gastric cancer | (Liu et al., 2017) |
| Hsa-miR-146a | mPGES-2 | Bone marrow-derived mesenchymal stem cells | (Matysiak et al., 2013) |
| Hsa-miR-146a | COX-2 | COPD | (Sato et al., 2010) |
| Hsa-miR-146a | COX-2 | Astrocytes | (Iyer et al., 2012) |
| Hsa-miR-146a | COX-2 | Colon cancer | (Zhang et al., 2019) |
| Hsa-miR-146a | COX-2 | Lung cancer | (Cornett and Lutz, 2014) |
| Hsa-miR-146a | COX-2 | COPD | (Wang et al., 2015) |
| Mmu-miR-199a | COX-2 | Mouse uterus, endometrial cancer | (Chakrabarty et al., 2007; Daikoku et al., 2008) |
| Mmu-miR-101a | |||
| Hsa-miR-101 | COX-2 | Colon cancer | (Strillacci et al., 2009) |
| Hsa-miR-101 | COX-2 | Endometrial serous carcinoma | (Hiroki et al., 2010) |
| Hsa-miR-101a | COX-2 | Mammary gland | (Tanaka et al., 2009) |
| Hsa-miR-101 | COX-2 | Gastric cancer | (He et al., 2012) |
| Hsa-miR-101 | COX-2 | Prostate cancer | (Hao et al., 2011) |
| Hsa-miR-101-3p | COX-2 | Esophageal squamous cell cancer | (Gong et al., 2016) |
| Hsa-miR-16 | COX-2 | Cervical cancer | (Jing et al., 2005) |
| Hsa-miR-16 | COX-2 | Hepatocellular carcinoma | (Agra Andrieu et al., 2012) |
| Hsa-miR-16 | COX-2 | Monocytes (THP-1 cells) | (Shanmugam et al., 2008) |
| Hsa-miR-137 | COX-2 | Glioma | (Chen et al., 2012) |
| Hsa-miR-143 | COX-2 | Amnion mesenchymal cells | (Kim et al., 2011) |
| Hsa-miR-542-3p | COX-2 | Colon cancer | (Moore et al., 2012) |
| Hsa-miR-574-5p | mPGES-1 | Lung cancer (NSCLC) | (Saul et al., 2019) |
| Hsa-miR-21 | 15-PGDH | Cholangiocarcinoma | (Lu et al., 2014) |
| Hsa-miR-21 | 15-PGDH | Tongue squamous cell cancer | (He et al., 2016) |
| Hsa-miR-21 | 15-PGDH | Gastric cancer | (Li et al., 2019) |
| Hsa-miR-21 | 15-PGDH | Colon cancer | (Monteleone et al., 2019) |
| Hsa-miR-26a/b | 15-PGDH | Cholangiocarcinoma | (Yao et al., 2015) |
| Hsa-miR-620 | 15-PGDH | Prostate adenocarcinoma cell line (DU145); breast cancer cell line (MDA-MB-231) | (Huang et al., 2015) |
| Hsa-miR-218 | 15-PGDH | Synovial mesenchymal stem cells (SMSCs) | (Cong et al., 2017) |
| Hsa-miR146b-3p | 15-PGDH | Cervical cancer | (Yao et al., 2018) |